On March 26th, US pharmaceutical giant Merck announced that its new drug for treating a deadly lung disease has been approved by the US Food and Drug Administration (FDA). Affected by this, the US stock market closed overnight, and Merck's stock price surged nearly 5%, reaching a historic high. The latest total market value rose to $333.7 billion (approximately RMB 2400 billion). The drug is marketed as Winrevair and is used to treat pulmonary arterial hypertension (PAH). Each bottle is priced at up to $14000 (approximately RMB 100000), and the annual cost is as high as $242000 (approximately RMB 1.74 million). Wall Street analysts are optimistic that Winrevair's annual sales may reach as high as $7.5 billion (approximately RMB 54 billion).